Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Multiple Myeloma
38%
Acute Myeloid Leukemia
29%
Multiple Myeloma Patients
27%
Overall Survival
25%
Newly Diagnosed multiple Myeloma
20%
High-risk Myeloma
16%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
Progression-free Survival
15%
Tyrosine Kinase Inhibitor
14%
Chimeric Antigen Receptor T-cell Therapy
13%
Autologous Transplantation
13%
Chronic Myeloid Leukemia
11%
Allogeneic
11%
Minimal Residual Disease
11%
Pretransplant
11%
Diagnostic Performance
10%
Relapsed or Refractory
10%
Leukemia Patients
10%
High-risk Cytogenetics
10%
Lenalidomide
10%
High Risk
10%
Ponatinib
9%
Maintenance Therapy
8%
Very Good Partial Response
8%
MD Anderson Cancer Center
8%
Multivariate Analysis
8%
Hematopoietic Cell Transplantation
8%
Post-transplant Management
8%
Hemophagocytic Lymphohistiocytosis
8%
Tertiary Care Hospital
8%
Confidence Interval
8%
Hazard Ratio
7%
Non-relapse Mortality
7%
Single Center
7%
Retrospective Analysis
7%
Myelodysplastic Syndrome
7%
Israeli
7%
Sorafenib
7%
Single-center Experience
7%
Vascular Adverse Events
6%
Newly Diagnosed
6%
Del17p
6%
Premature Aging
6%
Italian Studies
6%
Human Endothelial Cells
6%
Collagen
6%
COVID-19 Pandemic
6%
Anti-collagen Antibody
6%
Center Experience
6%
Medicine and Dentistry
Multiple Myeloma
65%
Transplantation
32%
Autologous Hematopoietic Stem Cell Transplantation
31%
Hematopoietic Stem Cell
30%
Cell Transplantation
28%
Overall Survival
28%
Acute Myeloid Leukemia
26%
Progression Free Survival
23%
Disease
21%
Diffuse Large B-Cell Lymphoma
18%
Stem Cell Transplant
16%
Autologous Stem Cell Transplantation
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
13%
Lenalidomide
13%
Diagnosis
12%
Malignant Neoplasm
11%
Tyrosine-Kinase Inhibitor
11%
Chronic Myelogenous Leukemia
11%
Retrospective Study
11%
Hematopoietic Stem Cell Transplantation
10%
Minimal Residual Disease
10%
Ponatinib
9%
Adverse Event
8%
Plasma Cell
8%
Maintenance Therapy
8%
Multivariate Analysis
7%
Hazard Ratio
7%
Hemophagocytic Syndrome
7%
Myelodysplastic Syndrome
7%
Azacitidine
7%
Endothelial Cell
7%
Flow Cytometry
6%
Systematic Review
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Biopsy
6%
Meta-Analysis
6%
Venetoclax
6%
Autograft
6%
Antiinfective Agent
6%
Non-Hodgkin Lymphoma
6%
Cancer
6%
Infection
6%
Autotransplantation
5%
Imatinib
5%
Nilotinib
5%
Dasatinib
5%
Bosutinib
5%